Genedrive PLC’s (LON:GDR) David Budd speaks to Proactive London's Andrew Scott soon after announcing their test for recognising the risk of antibiotic-induced hearing loss in infants obtained a European standard CE marking.
The kit will be used in critical care settings to screen babies for a genetic mutation, MT-RNR1, which if present, can cause lifelong deafness if they are prescribed with the antibiotic gentamicin.